XML 46 R37.htm IDEA: XBRL DOCUMENT
v3.22.1

Collaborations and Other Arrangements (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Apr. 30, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | $ 7,810.0 | $ 6,805.6 |
Petra | Subsequent Event |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Acquired IPR&D and development milestones | $ 335.0 |  |  |
China |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 406.5 | 362.2 |
Jardiance |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 419.4 | 312.0 |
Trajenta |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 92.0 | 94.6 |
Basaglar |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 191.5 | 246.6 |
Olumiant® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 255.6 | 193.8 |
COVID-19 Antibodies |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 1,469.8 | 810.1 |
Tyvyt® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Revenue |  | 85.5 | $ 109.7 |
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 131.1 |  | $ 136.1
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 82.0 |  | 88.5
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | $ (144.6) |  | (149.3)
Royalty Agreement Terms | Olumiant® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Collaborative arrangement, rights and obligations, percentage (up to) |  | 20.00% |  |
Milestone Payments, Capitalized as Intangible Assets | Olumiant® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | $ 260.0 |  | 260.0
Milestone Payments, Capitalized as Intangible Assets | Tyvyt® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  |  |  | $ 40.0
Milestone Payments, Development and Regulatory | Olumiant® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 70.0 |  |
Milestone Payments, Development and Regulatory | Lebrikizumab |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 85.0 |  |
Milestone Payments, Sales-based | Olumiant® |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 100.0 |  |
Milestone Payments, Sales-based | Lebrikizumab |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 1,250.0 |  |
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | Non-CHINA |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 825.0 |  |
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | China |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 195.0 |  |
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | 180.0 |  |
Roche | Milestone Payments, Sales-based | Lebrikizumab |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |
Potential achievements |  | $ 1,030.0 |  |

X
- Definition Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes. + References No definition available. + Details
Name: | lly_CollaborativeArrangementRightsAndObligationsPercent
Namespace Prefix: | lly_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Terms or rights and obligations under collaborative arrangements. + References No definition available. + Details
Name: | lly_CollaborativeArrangementRightsAndObligationsRightsObligations
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Payments for Asset Acquisitions + References No definition available. + Details
Name: | lly_PaymentsForAssetAcquisitions
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_JardianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_TrajentaBIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_BasaglarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OlumiantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_TYVYTMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsCapitalizedAsIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_LebrikizumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=lly_InnoventBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSuccessBasedRegulatoryAndSalesBasedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=lly_NonCHINAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=lly_RocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |